

## Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

### Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information  
Full Analysis Dataset : GLOBAL**

Number of prospective patients (C1+C2+C3+C4+C5 )	51270
Number of enrolling sites	1314
Number of enrolling countries	35
Enrolment period	02MAR2010 - 27JUL2016
Duration of enrolment (months)	76.9

**Table 02: Patients by region, country, and cohort**  
**Full Analysis Dataset : GLOBAL**

Region	Country	Cohort 1 Retrospective patients (N=5069)	Cohort 1 Prospective patients (N=5501)	Cohort 2 (N=11659)	Cohort 3 (N=11468)	Cohort 4 (N=11270)	Cohort 5 (N=11372)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
Europe		3329	3224	7621	6629	5618	5763	28855	23092
	Austria	120	146	122	47	79	69	463	394
	Belgium	0	0	403	515	387	389	1694	1305
	Czech Republic	0	0	521	427	403	492	1843	1351
	Denmark	135	90	162	56	85	135	528	393
	Finland	94	85	131	113	10	20	359	339
	France	261	268	470	330	331	401	1800	1399
	Germany	799	917	917	649	517	524	3524	3000
	Hungary	0	0	339	364	306	352	1361	1009
	Italy	391	452	529	325	468	417	2191	1774
	Netherlands	93	106	410	357	156	158	1187	1029
	Norway	75	48	69	95	31	29	272	243
	Poland	411	499	606	506	423	366	2400	2034
	Russia	0	0	586	645	425	472	2128	1656
	Spain	351	450	617	558	461	335	2421	2086
	Sweden	270	95	440	290	235	161	1221	1060
	Switzerland	0	0	0	0	27	61	88	27
	Ukraine	0	0	469	450	424	482	1825	1343
	United Kingdom	329	68	830	902	850	900	3550	2650
Asia		1001	1581	2357	3206	3973	3596	14713	11117
	China	305	495	444	504	530	487	2460	1973
	India	0	0	317	334	241	420	1312	892
	Japan	149	248	579	1119	1774	1138	4858	3720
	Korea	547	838	757	590	490	523	3198	2675
	Singapore	0	0	70	71	62	99	302	203
	Thailand	0	0	190	456	415	433	1494	1061
	Turkey	0	0	0	0	318	395	713	318

**Table 02: Patients by region, country, and cohort**  
**Full Analysis Dataset : GLOBAL**

Region	Country	Cohort 1 Retrospective patients (N=5069)	Cohort 1 Prospective patients (N=5501)	Cohort 2 (N=11659)	Cohort 3 (N=11468)	Cohort 4 (N=11270)	Cohort 5 (N=11372)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
	United Arab Emirates	0	0	0	132	143	101	376	275
North America		156	81	268	324	460	455	1588	1133
	Canada	156	81	268	202	148	183	882	699
	United States	0	0	0	122	312	272	706	434
Latin America		437	410	1026	1064	829	835	4164	3329
	Argentina	0	0	306	325	213	187	1031	844
	Brazil	146	97	248	230	231	234	1040	806
	Chile	0	0	182	318	211	260	971	711
	Mexico	291	313	290	191	174	154	1122	968
Rest Of World		146	205	387	245	390	723	1950	1227
	Australia	146	205	221	107	134	190	857	667
	Egypt	0	0	0	0	114	348	462	114
	South Africa	0	0	166	138	142	185	631	446

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
Sex, n(%)	n (missing)	5069 (0)	5501 (0)	11659 (0)	11468 (0)	11270 (0)	11371 (1)	51269 (1)	39898 (0)
	Male	2910 (57.4)	3099 (56.3)	6543 (56.1)	6275 (54.7)	6312 (56.0)	6372 (56.0)	28601 (55.8)	22229 (55.7)
	Female	2159 (42.6)	2402 (43.7)	5116 (43.9)	5193 (45.3)	4958 (44.0)	4999 (44.0)	22668 (44.2)	17669 (44.3)
Age at Diagnosis (Years)	n (missing)	5068 (1)	5501 (0)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51270 (0)	39898 (0)
	Mean (SD)	69.4 (10.7)	69.8 (11.5)	69.8 (11.4)	69.6 (11.4)	69.6 (11.7)	69.7 (11.7)	69.7 (11.5)	69.7 (11.5)
	Median (IQR)	71.0 (63.0 to 77.0)	71.0 (63.0 to 78.0)	71.0 (63.0 to 78.0)	71.0 (63.0 to 78.0)	71.0 (62.0 to 78.0)	71.0 (62.0 to 78.0)	71.0 (63.0 to 78.0)	71.0 (63.0 to 78.0)
	Min to Max	24 to 105	18 to 101	18 to 99	19 to 101	18 to 105	19 to 101	18 to 105	18 to 105
Age Group, n(%)	n (missing)	5068 (1)	5501 (0)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51270 (0)	39898 (0)
	<65	1519 (30.0)	1600 (29.1)	3494 (30.0)	3423 (29.8)	3435 (30.5)	3475 (30.6)	15427 (30.1)	11952 (30.0)
	65-74	1796 (35.4)	1833 (33.3)	3700 (31.7)	3790 (33.0)	3716 (33.0)	3645 (32.1)	16684 (32.5)	13039 (32.7)
	>=75	1753 (34.6)	2068 (37.6)	4465 (38.3)	4255 (37.1)	4119 (36.5)	4252 (37.4)	19159 (37.4)	14907 (37.4)
Time since AF Diagnosis (Weeks)	n (missing)	5068 (1)	4405 (1096)	8923 (2736)	8329 (3139)	7863 (3407)	7958 (3414)	37478 (13792)	29520 (10378)
	Mean (SD)	60.54 (23.63)	2.22 (1.78)	2.02 (1.69)	2.03 (1.70)	1.95 (1.70)	1.94 (1.70)	2.01 (1.71)	2.03 (1.71)
	Median (IQR)	57.15 (39.20 to 80.50)	1.80 (0.70 to 3.70)	1.50 (0.50 to 3.20)	1.50 (0.50 to 3.20)	1.40 (0.50 to 3.10)	1.40 (0.50 to 3.10)	1.50 (0.50 to 3.20)	1.50 (0.50 to 3.20)
	Min to Max	26.1 to 104.2	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 14.2	0.1 to 6.0	0.1 to 14.2	0.1 to 14.2
Race, n(%)	n (missing)	4849 (0)	5349 (0)	11280 (0)	11224 (0)	11073 (0)	11093 (0)	50019 (0)	38926 (0)
	Caucasian	3298 (68.0)	3276 (61.2)	7799 (69.1)	7124 (63.5)	6528 (59.0)	6868 (61.9)	31595 (63.2)	24727 (63.5)
	Hispanic/Latino	447 (9.2)	416 (7.8)	844 (7.5)	772 (6.9)	615 (5.6)	668 (6.0)	3315 (6.6)	2647 (6.8)
	Afro-Caribbean	19 (0.4)	8 (0.1)	18 (0.2)	27 (0.2)	69 (0.6)	110 (1.0)	232 (0.5)	122 (0.3)

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
	Asian (Not Chinese)	711 (14.7)	1096 (20.5)	1908 (16.9)	2617 (23.3)	3119 (28.2)	2639 (23.8)	11379 (22.7)	8740 (22.5)
	Chinese	307 (6.3)	493 (9.2)	484 (4.3)	564 (5.0)	573 (5.2)	570 (5.1)	2684 (5.4)	2114 (5.4)
	Mixed/Other	67 (1.4)	60 (1.1)	227 (2.0)	120 (1.1)	169 (1.5)	238 (2.1)	814 (1.6)	576 (1.5)
	Unknown	220	152	379	244	197	279	1251	972
Region, n(%)	n (missing)	5069 (0)	5501 (0)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51270 (0)	39898 (0)
	Europe	3329 (65.7)	3224 (58.6)	7621 (65.4)	6629 (57.8)	5618 (49.8)	5763 (50.7)	28855 (56.3)	23092 (57.9)
	North America	156 (3.1)	81 (1.5)	268 (2.3)	324 (2.8)	460 (4.1)	455 (4.0)	1588 (3.1)	1133 (2.8)
	Latin America	437 (8.6)	410 (7.5)	1026 (8.8)	1064 (9.3)	829 (7.4)	835 (7.3)	4164 (8.1)	3329 (8.3)
	Asia	1001 (19.7)	1581 (28.7)	2357 (20.2)	3206 (28.0)	3973 (35.3)	3596 (31.6)	14713 (28.7)	11117 (27.9)
	Rest Of World	146 (2.9)	205 (3.7)	387 (3.3)	245 (2.1)	390 (3.5)	723 (6.4)	1950 (3.8)	1227 (3.1)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	5065 (4)	5499 (2)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51268 (2)	39896 (2)
	Internal Medicine	1072 (21.2)	1116 (20.3)	2260 (19.4)	1911 (16.7)	2020 (17.9)	1904 (16.7)	9211 (18.0)	7307 (18.3)
	Cardiology	2809 (55.5)	3432 (62.4)	7184 (61.6)	7601 (66.3)	7633 (67.7)	7800 (68.6)	33650 (65.6)	25850 (64.8)
	Neurology	101 (2.0)	116 (2.1)	258 (2.2)	194 (1.7)	148 (1.3)	154 (1.4)	870 (1.7)	716 (1.8)
	Geriatrics	22 (0.4)	18 (0.3)	60 (0.5)	39 (0.3)	37 (0.3)	44 (0.4)	198 (0.4)	154 (0.4)
	Primary Care/General Practice	1061 (20.9)	817 (14.9)	1897 (16.3)	1723 (15.0)	1432 (12.7)	1470 (12.9)	7339 (14.3)	5869 (14.7)
Care Setting Location at Diagnosis, n(%)	n (missing)	5012 (5)	5499 (2)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51268 (2)	39896 (2)
	Hospital	2688 (53.6)	3301 (60.0)	7223 (62.0)	6596 (57.5)	6230 (55.3)	6468 (56.9)	29818 (58.2)	23350 (58.5)
	Office	1779 (35.5)	1496 (27.2)	2854 (24.5)	3475 (30.3)	3823 (33.9)	3757 (33.0)	15405 (30.0)	11648 (29.2)
	Anticoagulation clinic/thrombosi s centre	146 (2.9)	116 (2.1)	92 (0.8)	67 (0.6)	33 (0.3)	29 (0.3)	337 (0.7)	308 (0.8)
	Emergency room	399 (8.0)	586 (10.7)	1490 (12.8)	1330 (11.6)	1184 (10.5)	1118 (9.8)	5708 (11.1)	4590 (11.5)
	Unknown	52	-	-	-	-	-	-	-
Type of AF Diagnosed, n(%)	n (missing)	5065 (4)	5499 (2)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51268 (2)	39896 (2)
	Permanent	1840 (36.3)	778 (14.1)	1463 (12.5)	1397 (12.2)	1394 (12.4)	1476 (13.0)	6508 (12.7)	5032 (12.6)
	Persistent	982 (19.4)	909 (16.5)	1771 (15.2)	1687 (14.7)	1675 (14.9)	1621 (14.3)	7663 (14.9)	6042 (15.1)
	Paroxysmal	1567 (30.9)	1347 (24.5)	2985 (25.6)	3349 (29.2)	3330 (29.5)	3104 (27.3)	14115 (27.5)	11011 (27.6)
	New	676 (13.3)	2465 (44.8)	5440 (46.7)	5035 (43.9)	4871 (43.2)	5171 (45.5)	22982 (44.8)	17811 (44.6)



**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
Treatment Costs, n(%)	n (missing)	40 (0)	40 (2)	8540 (1)	10609 (0)	10544 (0)	10690 (0)	40423 (3)	29733 (3)
	Public insurance	29 (72.5)	35 (87.5)	6743 (79.0)	8445 (79.6)	8206 (77.8)	8079 (75.6)	31508 (77.9)	23429 (78.8)
	Private (insurance)	4 (10.0)	1 (2.5)	683 (8.0)	671 (6.3)	765 (7.3)	810 (7.6)	2930 (7.2)	2120 (7.1)
	Private (out of pocke	3 (7.5)	4 (10.0)	516 (6.0)	527 (5.0)	492 (4.7)	670 (6.3)	2209 (5.5)	1539 (5.2)
	Combination	4 (10.0)	-	598 (7.0)	966 (9.1)	1081 (10.3)	1131 (10.6)	3776 (9.3)	2645 (8.9)
	Unknown	5029	5459	3118	859	726	682	10844	10162
Treatment Sector, n(%)	n (missing)	341 (0)	351 (2)	9127 (1)	11272 (0)	11161 (0)	11284 (0)	43195 (3)	31911 (3)
	In the public sector	146 (42.8)	123 (35.0)	6756 (74.0)	8451 (75.0)	7682 (68.8)	7903 (70.0)	30915 (71.6)	23012 (72.1)
	In the private sector	195 (57.2)	228 (65.0)	2371 (26.0)	2821 (25.0)	3479 (31.2)	3381 (30.0)	12280 (28.4)	8899 (27.9)
	Unknown	4728	5148	2531	196	109	88	8072	7984

**Table 05 : Vital signs and life style  
Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
Height (cm)	n (missing)	4130 (939)	4817 (684)	8912 (2747)	8812 (2656)	8685 (2585)	8829 (2543)	40055 (11215)	31226 (8672)
	Mean (SD)	167.5 (9.9)	166.5 (9.8)	167.3 (10.2)	166.5 (10.5)	166.4 (10.4)	166.9 (10.4)	166.8 (10.3)	166.7 (10.3)
	Median (IQR)	168.0 (160.0 to 175.0)	167.0 (160.0 to 173.0)	168.0 (160.0 to 175.0)	167.0 (160.0 to 174.0)	166.0 (160.0 to 174.0)	167.0 (160.0 to 174.0)	167.0 (160.0 to 174.0)	167.0 (160.0 to 174.0)
	Min to Max	132 to 201	130 to 198	116 to 206	112 to 203	127 to 202	119 to 206	112 to 206	112 to 206
Weight (kg)	n (missing)	4130 (939)	4817 (684)	8912 (2747)	8812 (2656)	8685 (2585)	8829 (2543)	40055 (11215)	31226 (8672)
	Mean (SD)	78.0 (17.1)	76.0 (17.3)	78.7 (18.7)	77.6 (19.6)	76.9 (19.1)	78.1 (19.6)	77.6 (19.0)	77.5 (18.9)
	Median (IQR)	76.0 (67.0 to 88.0)	75.0 (64.0 to 86.0)	77.0 (66.0 to 89.0)	75.0 (64.0 to 89.0)	75.0 (64.0 to 88.0)	76.0 (65.0 to 90.0)	75.0 (65.0 to 88.0)	75.0 (65.0 to 88.0)
	Min to Max	34 to 182	30 to 193	29 to 227	31 to 202	25 to 220	30 to 210	25 to 227	25 to 227
BMI (kg/m <sup>2</sup> )	n (missing)	4130 (939)	4817 (684)	8912 (2747)	8812 (2656)	8685 (2585)	8829 (2543)	40055 (11215)	31226 (8672)
	Mean (SD)	27.7 (5.0)	27.3 (5.2)	28.0 (5.5)	27.8 (5.8)	27.6 (5.7)	27.9 (5.9)	27.8 (5.7)	27.7 (5.6)
	Median (IQR)	27.0 (24.0 to 30.0)	26.0 (24.0 to 30.0)	27.0 (24.0 to 31.0)	27.0 (24.0 to 31.0)	27.0 (24.0 to 31.0)	27.0 (24.0 to 31.0)	27.0 (24.0 to 31.0)	27.0 (24.0 to 31.0)
	Min to Max	12 to 56	11 to 68	14 to 77	13 to 85	9 to 75	12 to 78	9 to 85	9 to 85
BMI Category, n(%)	n (missing)	4130 (939)	4817 (684)	8912 (2747)	8812 (2656)	8685 (2585)	8829 (2543)	40055 (11215)	31226 (8672)
	<19	67 (1.6)	116 (2.4)	177 (2.0)	255 (2.9)	254 (2.9)	222 (2.5)	1024 (2.6)	802 (2.6)
	19-<25	1204 (29.2)	1622 (33.7)	2544 (28.5)	2710 (30.8)	2800 (32.2)	2755 (31.2)	12431 (31.0)	9676 (31.0)
	25-<30	1741 (42.2)	1865 (38.7)	3493 (39.2)	3219 (36.5)	3222 (37.1)	3239 (36.7)	15038 (37.5)	11799 (37.8)
	30-<40	1021 (24.7)	1113 (23.1)	2417 (27.1)	2308 (26.2)	2116 (24.4)	2280 (25.8)	10234 (25.5)	7954 (25.5)
	>=40	97 (2.3)	101 (2.1)	281 (3.2)	320 (3.6)	293 (3.4)	333 (3.8)	1328 (3.3)	995 (3.2)
Pulse (bpm)	n (missing)	4233 (836)	4977 (524)	10606 (1053)	10691 (777)	10587 (683)	10671 (701)	47532 (3738)	36861 (3037)
	Mean (SD)	84.5 (23.9)	88.5 (25.8)	90.6 (27.1)	90.7 (26.7)	90.2 (26.5)	91.0 (27.1)	90.4 (26.8)	90.2 (26.7)
	Median (IQR)	79.0 (68.0 to 94.0)	82.0 (70.0 to 100.0)	84.0 (70.0 to 106.0)	84.0 (70.0 to 106.0)	84.0 (70.0 to 105.0)	85.0 (71.0 to 105.0)	84.0 (70.0 to 105.0)	84.0 (70.0 to 105.0)
	Min to Max	34 to 242	34 to 203	30 to 210	29 to 250	34 to 250	21 to 214	21 to 250	29 to 250

**Table 05 : Vital signs and life style  
Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
Systolic BP (mm Hg)	n (missing)	4491 (578)	5143 (358)	10807 (852)	10798 (670)	10633 (637)	10644 (728)	48025 (3245)	37381 (2517)
	Mean (SD)	134.6 (19.5)	133.5 (20.3)	134.2 (19.6)	133.6 (20.2)	132.9 (19.4)	133.3 (20.0)	133.5 (19.9)	133.6 (19.8)
	Median (IQR)	132.0 (120.0 to 145.0)	130.0 (120.0 to 145.0)	132.0 (120.0 to 145.0)	130.0 (120.0 to 144.0)	130.0 (120.0 to 144.0)	130.0 (120.0 to 145.0)	130.0 (120.0 to 145.0)	131.0 (120.0 to 145.0)
	Min to Max	60 to 240	40 to 250	64 to 242	60 to 270	62 to 260	55 to 276	40 to 276	40 to 270
Diastolic BP (mm Hg)	n (missing)	4491 (578)	5143 (358)	10807 (852)	10798 (670)	10633 (637)	10644 (728)	48025 (3245)	37381 (2517)
	Mean (SD)	80.3 (12.0)	79.8 (13.0)	80.1 (12.6)	79.9 (13.1)	79.1 (12.9)	79.6 (13.0)	79.7 (12.9)	79.7 (12.9)
	Median (IQR)	80.0 (70.0 to 88.0)	80.0 (70.0 to 88.0)	80.0 (70.0 to 89.0)	80.0 (70.0 to 88.0)	80.0 (70.0 to 87.0)	80.0 (70.0 to 89.0)	80.0 (70.0 to 88.0)	80.0 (70.0 to 88.0)
	Min to Max	40 to 149	26 to 164	30 to 150	27 to 180	29 to 170	30 to 147	26 to 180	26 to 180
LVEF (%)	n (missing)	2837 (2232)	3314 (2187)	6432 (5227)	6633 (4835)	6802 (4468)	6785 (4587)	29966 (21304)	23181 (16717)
	Mean (SD)	56.6 (12.4)	56.7 (12.1)	55.9 (12.5)	56.3 (12.7)	57.2 (12.4)	56.2 (12.5)	56.5 (12.5)	56.5 (12.5)
	Median (IQR)	60.0 (50.0 to 65.0)	59.5 (50.0 to 65.0)	59.0 (50.0 to 65.0)	59.0 (50.0 to 65.0)	60.0 (50.0 to 65.0)	60.0 (50.0 to 65.0)	60.0 (50.0 to 65.0)	60.0 (50.0 to 65.0)
	Min to Max	10 to 100	15 to 90	10 to 92	10 to 93	10 to 91	10 to 90	10 to 93	10 to 93
LVEF Category, n (missing) n(%)		2837 (2232)	3314 (2187)	6432 (5227)	6633 (4835)	6802 (4468)	6785 (4587)	29966 (21304)	23181 (16717)
	<40%	277 (9.8)	304 (9.2)	669 (10.4)	692 (10.4)	634 (9.3)	718 (10.6)	3017 (10.1)	2299 (9.9)
	>=40%	2560 (90.2)	3010 (90.8)	5763 (89.6)	5941 (89.6)	6168 (90.7)	6067 (89.4)	26949 (89.9)	20882 (90.1)
History of Hypertension, n(%)	n (missing)	5065 (4)	5499 (2)	11659 (0)	11425 (0)	11226 (0)	11322 (0)	51131 (2)	39809 (2)
	No	1079 (21.3)	1275 (23.2)	2489 (21.3)	2658 (23.3)	2843 (25.3)	2841 (25.1)	12106 (23.7)	9265 (23.3)
	Yes	3986 (78.7)	4224 (76.8)	9170 (78.7)	8767 (76.7)	8383 (74.7)	8481 (74.9)	39025 (76.3)	30544 (76.7)

**Table 05 : Vital signs and life style  
Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
	Unknown	-	-	-	43	44	50	137	87
Alcohol Consumption, n(%)	n (missing)	4514 (4)	5011 (2)	9715 (0)	9492 (0)	9619 (1)	9613 (0)	43450 (3)	33837 (3)
	Abstinent	2395 (53.1)	2793 (55.7)	5165 (53.2)	5190 (54.7)	5367 (55.8)	5550 (57.7)	24065 (55.4)	18515 (54.7)
	Light	1650 (36.6)	1679 (33.5)	3343 (34.4)	3108 (32.7)	3115 (32.4)	2970 (30.9)	14215 (32.7)	11245 (33.2)
	Moderate	384 (8.5)	409 (8.2)	960 (9.9)	966 (10.2)	927 (9.6)	888 (9.2)	4150 (9.6)	3262 (9.6)
	Heavy	85 (1.9)	130 (2.6)	247 (2.5)	228 (2.4)	210 (2.2)	205 (2.1)	1020 (2.3)	815 (2.4)
	Unknown	551	488	1944	1976	1650	1759	7817	6058
Smoker, n(%)	n (missing)	4718 (4)	5182 (2)	10438 (0)	10426 (0)	10359 (0)	10358 (0)	46763 (2)	36405 (2)
	No	3019 (64.0)	3381 (65.2)	6765 (64.8)	6838 (65.6)	6823 (65.9)	6784 (65.5)	30591 (65.4)	23807 (65.4)
	Ex-smoker	1259 (26.7)	1239 (23.9)	2535 (24.3)	2425 (23.3)	2459 (23.7)	2408 (23.2)	11066 (23.7)	8658 (23.8)
	Current smoker	440 (9.3)	562 (10.8)	1138 (10.9)	1163 (11.2)	1077 (10.4)	1166 (11.3)	5106 (10.9)	3940 (10.8)
	Unknown	347	317	1221	1042	911	1014	4505	3491

**Table 06 : Clinical History**  
**Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
Congestive heart failure, n(%)	n (missing)	5065 (4)	5499 (2)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51268 (2)	39896 (2)
	No	4101 (81.0)	4473 (81.3)	9153 (78.5)	9152 (79.8)	9099 (80.7)	9131 (80.3)	41008 (80.0)	31877 (79.9)
	Yes	964 (19.0)	1026 (18.7)	2506 (21.5)	2316 (20.2)	2171 (19.3)	2241 (19.7)	10260 (20.0)	8019 (20.1)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	910 (4105)	993 (4475)	2329 (9153)	2108 (9152)	1941 (9099)	1985 (9131)	9356 (41010)	7371 (31879)
	I	167 (18.4)	183 (18.4)	405 (17.4)	460 (21.8)	383 (19.7)	361 (18.2)	1792 (19.2)	1431 (19.4)
	II	493 (54.2)	483 (48.6)	1175 (50.5)	993 (47.1)	918 (47.3)	967 (48.7)	4536 (48.5)	3569 (48.4)
	III	211 (23.2)	271 (27.3)	642 (27.6)	561 (26.6)	557 (28.7)	574 (28.9)	2605 (27.8)	2031 (27.6)
	IV	39 (4.3)	56 (5.6)	107 (4.6)	94 (4.5)	83 (4.3)	83 (4.2)	423 (4.5)	340 (4.6)
	Unknown	54	33	177	208	230	256	904	648
Coronary artery disease, n(%)	n (missing)	5065 (4)	5499 (2)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51268 (2)	39896 (2)
	No	4102 (81.0)	4440 (80.7)	9300 (79.8)	8968 (78.2)	8801 (78.1)	8724 (76.7)	40233 (78.5)	31509 (79.0)
	Yes	963 (19.0)	1059 (19.3)	2359 (20.2)	2500 (21.8)	2469 (21.9)	2648 (23.3)	11035 (21.5)	8387 (21.0)
Acute coronary syndrome, n(%)	n (missing)	5065 (4)	5499 (2)	11656 (0)	11404 (0)	11205 (0)	11291 (0)	51055 (2)	39764 (2)
	No	4578 (90.4)	4946 (89.9)	10596 (90.9)	10373 (91.0)	10112 (90.2)	10168 (90.1)	46195 (90.5)	36027 (90.6)
	Yes	487 (9.6)	553 (10.1)	1060 (9.1)	1031 (9.0)	1093 (9.8)	1123 (9.9)	4860 (9.5)	3737 (9.4)
	Unknown	-	-	3	64	65	81	213	132
Carotid Occlusive Disease, n(%)	n (missing)	5065 (4)	5499 (2)	11647 (0)	11279 (0)	11045 (0)	11108 (0)	50578 (2)	39470 (2)
	No	4889 (96.5)	5306 (96.5)	11333 (97.3)	10919 (96.8)	10710 (97.0)	10795 (97.2)	49063 (97.0)	38268 (97.0)

**Table 06 : Clinical History**  
**Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
	Yes	176 (3.5)	193 (3.5)	314 (2.7)	360 (3.2)	335 (3.0)	313 (2.8)	1515 (3.0)	1202 (3.0)
	Unknown	-	-	12	189	225	264	690	426
PE or DVT, n(%)	n (missing)	5065 (4)	5499 (2)	11649 (0)	11387 (0)	11197 (0)	11256 (0)	50988 (2)	39732 (2)
	No	4923 (97.2)	5337 (97.1)	11332 (97.3)	11098 (97.5)	10923 (97.6)	10964 (97.4)	49654 (97.4)	38690 (97.4)
	Yes	142 (2.8)	162 (2.9)	317 (2.7)	289 (2.5)	274 (2.4)	292 (2.6)	1334 (2.6)	1042 (2.6)
	Unknown	-	-	10	81	73	116	280	164
Other Thromboemboli sm, n(%)	n (missing)	5064 (5)	5499 (2)	11525 (134)	0 (11468)	0 (11270)	0 (11372)	17024 (34246)	17024 (22874)
	No	4982 (98.4)	5432 (98.8)	11413 (99.0)	-	-	-	16845 (98.9)	16845 (98.9)
	Yes	82 (1.6)	67 (1.2)	112 (1.0)	-	-	-	179 (1.1)	179 (1.1)
Systemic Embolization, n(%)	n (missing)	5065 (4)	5499 (2)	11649 (0)	11389 (0)	11195 (0)	11252 (0)	50984 (2)	39732 (2)
	No	5020 (99.1)	5464 (99.4)	11575 (99.4)	11304 (99.3)	11116 (99.3)	11193 (99.5)	50652 (99.3)	39459 (99.3)
	Yes	45 (0.9)	35 (0.6)	74 (0.6)	85 (0.7)	79 (0.7)	59 (0.5)	332 (0.7)	273 (0.7)
	Unknown	-	-	10	79	75	120	284	164
Coronary Artery Bypass Graft, n(%)	n (missing)	4605 (4)	4998 (2)	11651 (0)	11418 (0)	11229 (0)	11312 (0)	50608 (2)	39296 (2)
	No	4504 (97.8)	4902 (98.1)	11244 (96.5)	11067 (96.9)	10888 (97.0)	10908 (96.4)	49009 (96.8)	38101 (97.0)
	Yes	101 (2.2)	96 (1.9)	407 (3.5)	351 (3.1)	341 (3.0)	404 (3.6)	1599 (3.2)	1195 (3.0)
	Unknown	460	501	8	50	41	60	660	600
Stroke/TIA, n(%)	n (missing)	5065 (4)	5499 (2)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51268 (2)	39896 (2)

**Table 06 : Clinical History**  
**Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
	No	4268 (84.3)	4770 (86.7)	10202 (87.5)	10230 (89.2)	10023 (88.9)	10185 (89.6)	45410 (88.6)	35225 (88.3)
	Yes	797 (15.7)	729 (13.3)	1457 (12.5)	1238 (10.8)	1247 (11.1)	1187 (10.4)	5858 (11.4)	4671 (11.7)
Stroke, n(%)	n (missing)	5065 (4)	5499 (2)	11651 (0)	11415 (0)	11227 (0)	11301 (0)	51093 (2)	39792 (2)
	No	4515 (89.1)	5027 (91.4)	10666 (91.5)	10617 (93.0)	10397 (92.6)	10559 (93.4)	47266 (92.5)	36707 (92.2)
	Yes	550 (10.9)	472 (8.6)	985 (8.5)	798 (7.0)	830 (7.4)	742 (6.6)	3827 (7.5)	3085 (7.8)
	Unknown	-	-	8	53	43	71	175	104
History of Bleeding, n(%)	n (missing)	5065 (4)	5499 (2)	11648 (0)	11406 (0)	11211 (0)	11291 (0)	51055 (2)	39764 (2)
	No	4870 (96.2)	5327 (96.9)	11323 (97.2)	11123 (97.5)	10944 (97.6)	11036 (97.7)	49753 (97.4)	38717 (97.4)
	Yes	195 (3.8)	172 (3.1)	325 (2.8)	283 (2.5)	267 (2.4)	255 (2.3)	1302 (2.6)	1047 (2.6)
	Unknown	-	-	11	62	59	81	213	132
Hypercholester olaemia, n(%)	n (missing)	5065 (4)	5499 (2)	11652 (1)	10929 (0)	10726 (0)	10859 (0)	49665 (3)	38806 (3)
	No	2951 (58.3)	3472 (63.1)	6804 (58.4)	6290 (57.6)	6207 (57.9)	6255 (57.6)	29028 (58.4)	22773 (58.7)
	Yes	2114 (41.7)	2027 (36.9)	4848 (41.6)	4639 (42.4)	4519 (42.1)	4604 (42.4)	20637 (41.6)	16033 (41.3)
	Unknown	-	-	6	539	544	513	1602	1089
Diabetes, n(%)	n (missing)	5064 (5)	5499 (2)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51268 (2)	39896 (2)
	No	3959 (78.2)	4284 (77.9)	9124 (78.3)	9007 (78.5)	8780 (77.9)	8756 (77.0)	39951 (77.9)	31195 (78.2)
	Type I	47 (0.9)	57 (1.0)	77 (0.7)	130 (1.1)	118 (1.0)	123 (1.1)	505 (1.0)	382 (1.0)
	Type II	1058 (20.9)	1158 (21.1)	2458 (21.1)	2331 (20.3)	2372 (21.0)	2493 (21.9)	10812 (21.1)	8319 (20.9)
Diabetes, n(%)	n (missing)	5064 (5)	5499 (2)	11659 (0)	11468 (0)	11270 (0)	11372 (0)	51268 (2)	39896 (2)
	No	3959 (78.2)	4284 (77.9)	9124 (78.3)	9007 (78.5)	8780 (77.9)	8756 (77.0)	39951 (77.9)	31195 (78.2)
	Yes	1105 (21.8)	1215 (22.1)	2535 (21.7)	2461 (21.5)	2490 (22.1)	2616 (23.0)	11317 (22.1)	8701 (21.8)
Cirrhosis, n(%)	n (missing)	5065 (4)	5499 (2)	11647 (0)	11204 (0)	11045 (0)	11131 (0)	50526 (2)	39395 (2)
	No	5049 (99.7)	5460 (99.3)	11592 (99.5)	11144 (99.5)	10985 (99.5)	11056 (99.3)	50237 (99.4)	39181 (99.5)

**Table 06 : Clinical History**  
**Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
	Yes	16 (0.3)	39 (0.7)	55 (0.5)	60 (0.5)	60 (0.5)	75 (0.7)	289 (0.6)	214 (0.5)
	Unknown	-	-	12	264	225	241	742	501
Dementia, n(%)	n (missing)	5065 (4)	5499 (2)	11652 (0)	11363 (0)	11208 (0)	11283 (0)	51005 (2)	39722 (2)
	No	4996 (98.6)	5418 (98.5)	11469 (98.4)	11217 (98.7)	11032 (98.4)	11122 (98.6)	50258 (98.5)	39136 (98.5)
	Yes	69 (1.4)	81 (1.5)	183 (1.6)	146 (1.3)	176 (1.6)	161 (1.4)	747 (1.5)	586 (1.5)
	Unknown	-	-	7	105	62	89	263	174
Hyperthyroidism, n(%)	n (missing)	5065 (4)	5499 (2)	11654 (0)	11194 (0)	10921 (0)	11035 (0)	50303 (2)	39268 (2)
	No	4948 (97.7)	5358 (97.4)	11463 (98.4)	11020 (98.4)	10743 (98.4)	10839 (98.2)	49423 (98.3)	38584 (98.3)
	Yes	117 (2.3)	141 (2.6)	191 (1.6)	174 (1.6)	178 (1.6)	196 (1.8)	880 (1.7)	684 (1.7)
	Unknown	-	-	5	274	349	337	965	628
Hypothyroidism, n(%)	n (missing)	5065 (4)	5499 (2)	11654 (0)	11189 (0)	10913 (0)	11025 (1)	50280 (3)	39255 (2)
	No	4781 (94.4)	5257 (95.6)	10964 (94.1)	10497 (93.8)	10247 (93.9)	10324 (93.6)	47289 (94.1)	36965 (94.2)
	Yes	284 (5.6)	242 (4.4)	690 (5.9)	692 (6.2)	666 (6.1)	701 (6.4)	2991 (5.9)	2290 (5.8)
	Unknown	-	-	5	279	357	346	987	641
Vascular Disease, n(%)	n (missing)	5069 (0)	5501 (0)	11656 (3)	11431 (37)	11228 (42)	11303 (69)	51119 (151)	39816 (82)
	No	4292 (84.7)	4654 (84.6)	10019 (86.0)	9749 (85.3)	9576 (85.3)	9603 (85.0)	43601 (85.3)	33998 (85.4)
	Yes	777 (15.3)	847 (15.4)	1637 (14.0)	1682 (14.7)	1652 (14.7)	1700 (15.0)	7518 (14.7)	5818 (14.6)
Moderate to Severe CKD, n(%)	n (missing)	5065 (4)	5498 (3)	11659 (0)	11468 (0)	11269 (1)	11372 (0)	51266 (4)	39894 (4)
	No	4536 (89.6)	5003 (91.0)	10395 (89.2)	10257 (89.4)	10133 (89.9)	10172 (89.4)	45960 (89.7)	35788 (89.7)
	Yes	529 (10.4)	495 (9.0)	1264 (10.8)	1211 (10.6)	1136 (10.1)	1200 (10.6)	5306 (10.3)	4106 (10.3)



Study ID: TRI08888

GARFIELD: International Registry of Patients Newly Diagnosed with AF

**Table 06 : Clinical History**  
**Full Analysis Dataset : GLOBAL**

**Table 07 : Treatment for stroke prophylaxis  
Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
Baseline Treatment, n(%)	n (missing)	4946 (0)	5312 (0)	11559 (0)	11350 (0)	11147 (0)	11275 (0)	50643 (0)	39368 (0)
	VKA	2444 (49.4)	2121 (39.9)	4214 (36.5)	3612 (31.8)	2941 (26.4)	2418 (21.4)	15306 (30.2)	12888 (32.7)
	VKA+AP	627 (12.7)	707 (13.3)	1398 (12.1)	1022 (9.0)	837 (7.5)	810 (7.2)	4774 (9.4)	3964 (10.1)
	FXA	29 (0.6)	71 (1.3)	566 (4.9)	1663 (14.7)	2764 (24.8)	3321 (29.5)	8385 (16.6)	5064 (12.9)
	FXA+AP	36 (0.7)	70 (1.3)	217 (1.9)	356 (3.1)	530 (4.8)	660 (5.9)	1833 (3.6)	1173 (3.0)
	DTI	17 (0.3)	47 (0.9)	637 (5.5)	815 (7.2)	721 (6.5)	759 (6.7)	2979 (5.9)	2220 (5.6)
	DTI+AP	8 (0.2)	34 (0.6)	176 (1.5)	146 (1.3)	132 (1.2)	122 (1.1)	610 (1.2)	488 (1.2)
	AP	1329 (26.9)	1604 (30.2)	3020 (26.1)	2281 (20.1)	1841 (16.5)	1842 (16.3)	10588 (20.9)	8746 (22.2)
	NONE	456 (9.2)	658 (12.4)	1331 (11.5)	1455 (12.8)	1381 (12.4)	1343 (11.9)	6168 (12.2)	4825 (12.3)
	Unknown	123	189	100	118	123	97	627	530
	VKA±AP	3071 (62.1)	2828 (53.2)	5612 (48.6)	4634 (40.8)	3778 (33.9)	3228 (28.6)	20080 (39.7)	16852 (42.8)
	FXA±AP	65 (1.3)	141 (2.7)	783 (6.8)	2019 (17.8)	3294 (29.6)	3981 (35.3)	10218 (20.2)	6237 (15.8)
	DTI±AP	25 (0.5)	81 (1.5)	813 (7.0)	961 (8.5)	853 (7.7)	881 (7.8)	3589 (7.1)	2708 (6.9)
	FXA/DTI	46 (0.9)	118 (2.2)	1203 (10.4)	2478 (21.8)	3485 (31.3)	4080 (36.2)	11364 (22.4)	7284 (18.5)
	FXA/DTI+AP	44 (0.9)	104 (2.0)	393 (3.4)	502 (4.4)	662 (5.9)	782 (6.9)	2443 (4.8)	1661 (4.2)
	FXA/DTI±AP	90 (1.8)	222 (4.2)	1596 (13.8)	2980 (26.3)	4147 (37.2)	4862 (43.1)	13807 (27.3)	8945 (22.7)
	AC	2490 (50.3)	2239 (42.1)	5417 (46.9)	6090 (53.7)	6426 (57.6)	6498 (57.6)	26670 (52.7)	20172 (51.2)
	AC+AP	671 (13.6)	811 (15.3)	1791 (15.5)	1524 (13.4)	1499 (13.4)	1592 (14.1)	7217 (14.3)	5625 (14.3)
	AC±AP	3161 (63.9)	3050 (57.4)	7208 (62.4)	7614 (67.1)	7925 (71.1)	8090 (71.8)	33887 (66.9)	25797 (65.5)

**Table 08: Treatment**  
**Full Analysis Dataset : GLOBAL**

	<b>Cohort 1 Retrospective (N=5069) (n %)</b>	<b>Cohort 1 Prospective (N=5501) (n %)</b>	<b>Cohort 2 (N=11659) (n %)</b>	<b>Cohort 3 (N=11468) (n %)</b>	<b>Cohort 4 (N=11270) (n %)</b>	<b>Cohort 5 (N=11372) (n %)</b>	<b>Total Prospective patients Cohorts 1 to 5 (N=51270)</b>	<b>Total Prospective patients Cohorts 1 to 4 (N=39898)</b>
<b>Anti-platelet (non mutually exclusive groups)</b>								
Glycoprotein inhibitors	4 (0.1)	11 (0.2)	33 (0.3)	12 (0.1)	-		56 (0.1)	56 (0.1)
ADP receptor/P2Y12 inhibitors	301 (5.9)	406 (7.4)	833 (7.1)	771 (6.7)	699 (6.2)	799 (7.0)	3508 (6.8)	2709 (6.8)
Prostaglandin Cox inhibitors	6 (0.1)	12 (0.2)	13 (0.1)	12 (0.1)	16 (0.1)	17 (0.1)	70 (0.1)	53 (0.1)
ASA	351 (6.9)	477 (8.7)	33 (0.3)	634 (5.5)	283 (2.5)	260 (2.3)	1687 (3.3)	1427 (3.6)
	1225 (24.2)	1476 (26.8)	4156 (35.6)	2927 (25.5)	2875 (25.5)	2880 (25.3)	14314 (27.9)	11434 (28.7)
<b>Anticoagulant drugs (non mutually exclusive groups)</b>								
VKA	3121 (61.6)	2933 (53.3)	5683 (48.7)	4714 (41.1)	3858 (34.2)	3304 (29.1)	20492 (40.0)	17188 (43.1)
FXa	111 (2.2)	240 (4.4)	861 (7.4)	2106 (18.4)	3386 (30.0)	4072 (35.8)	10665 (20.8)	6593 (16.5)
DTI	33 (0.7)	91 (1.7)	835 (7.2)	1006 (8.8)	879 (7.8)	910 (8.0)	3721 (7.3)	2811 (7.0)
Heparinoid	21 (0.4)	68 (1.2)	85 (0.7)	37 (0.3)	42 (0.4)	36 (0.3)	268 (0.5)	232 (0.6)
Heparins	136 (2.7)	277 (5.0)	1428 (12.2)	1109 (9.7)	803 (7.1)	740 (6.5)	4357 (8.5)	3617 (9.1)
Other	7 (0.1)	24 (0.4)	61 (0.5)	46 (0.4)	41 (0.4)	60 (0.5)	232 (0.5)	172 (0.4)

**Table 09 : Risk scores**  
**Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
CHADS2 Score	n (missing)	4910 (159)	5407 (94)	11395 (264)	11234 (234)	11031 (239)	11128 (244)	50195 (1075)	39067 (831)
	Mean (SD)	1.9 (1.2)	1.9 (1.1)	1.9 (1.1)	1.8 (1.1)	1.8 (1.1)	1.8 (1.1)	1.9 (1.1)	1.9 (1.1)
	Median (IQR)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	4910 (159)	5407 (94)	11395 (264)	11234 (234)	11031 (239)	11128 (244)	50195 (1075)	39067 (831)
	0	285 (5.8)	392 (7.2)	711 (6.2)	897 (8.0)	977 (8.9)	1027 (9.2)	4004 (8.0)	2977 (7.6)
	1	1803 (36.7)	1873 (34.6)	3808 (33.4)	3841 (34.2)	3814 (34.6)	3668 (33.0)	17004 (33.9)	13336 (34.1)
	2	1495 (30.4)	1805 (33.4)	3978 (34.9)	3903 (34.7)	3730 (33.8)	3832 (34.4)	17248 (34.4)	13416 (34.3)
	3	829 (16.9)	826 (15.3)	1784 (15.7)	1701 (15.1)	1571 (14.2)	1671 (15.0)	7553 (15.0)	5882 (15.1)
	4	362 (7.4)	377 (7.0)	812 (7.1)	649 (5.8)	697 (6.3)	690 (6.2)	3225 (6.4)	2535 (6.5)
	5	119 (2.4)	107 (2.0)	258 (2.3)	217 (1.9)	214 (1.9)	209 (1.9)	1005 (2.0)	796 (2.0)
	6	17 (0.3)	27 (0.5)	44 (0.4)	26 (0.2)	28 (0.3)	31 (0.3)	156 (0.3)	125 (0.3)
CHA2DS2- VASc Score	n (missing)	4910 (159)	5407 (94)	11390 (269)	11176 (292)	10962 (308)	11017 (355)	49952 (1318)	38935 (963)
	Mean (SD)	3.2 (1.6)	3.2 (1.6)	3.2 (1.6)	3.2 (1.6)	3.1 (1.6)	3.1 (1.6)	3.2 (1.6)	3.2 (1.6)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 9	0 to 9	0 to 9	0 to 9	0 to 9	0 to 9	0 to 9
CHA2DS2- VASc score categories, n(%)	n (missing)	4910 (159)	5407 (94)	11390 (269)	11176 (292)	10962 (308)	11017 (355)	49952 (1318)	38935 (963)
	0	87 (1.8)	142 (2.6)	255 (2.2)	290 (2.6)	360 (3.3)	357 (3.2)	1404 (2.8)	1047 (2.7)
	1	622 (12.7)	672 (12.4)	1328 (11.7)	1352 (12.1)	1357 (12.4)	1386 (12.6)	6095 (12.2)	4709 (12.1)
	2	992 (20.2)	1050 (19.4)	2229 (19.6)	2260 (20.2)	2259 (20.6)	2167 (19.7)	9965 (19.9)	7798 (20.0)
	3	1146 (23.3)	1264 (23.4)	2783 (24.4)	2706 (24.2)	2652 (24.2)	2625 (23.8)	12030 (24.1)	9405 (24.2)
	4	1019 (20.8)	1169 (21.6)	2503 (22.0)	2493 (22.3)	2314 (21.1)	2458 (22.3)	10937 (21.9)	8479 (21.8)

**Table 09 : Risk scores**  
**Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Retrospective patients (N=5069) (n %)	Cohort 1 Prospective patients (N=5501) (n %)	Cohort 2 (N=11659) (n %)	Cohort 3 (N=11468) (n %)	Cohort 4 (N=11270) (n %)	Cohort 5 (N=11372) (n %)	Total Prospective patients Cohorts 1 to 5 (N=51270)	Total Prospective patients Cohorts 1 to 4 (N=39898)
	5	613 (12.5)	657 (12.2)	1336 (11.7)	1262 (11.3)	1206 (11.0)	1235 (11.2)	5696 (11.4)	4461 (11.5)
	6-9	431 (8.8)	453 (8.4)	956 (8.4)	813 (7.3)	814 (7.4)	789 (7.2)	3825 (7.7)	3036 (7.8)
HAS-BLED score	n (missing)	3032 (2037)	3540 (1961)	7275 (4384)	8587 (2881)	8814 (2456)	8760 (2612)	36976 (14294)	28216 (11682)
	Mean (SD)	1.5 (1.0)	1.5 (0.9)	1.5 (0.9)	1.4 (0.9)	1.3 (0.9)	1.3 (0.9)	1.4 (0.9)	1.4 (0.9)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 6	0 to 5	0 to 6	0 to 5	0 to 6	0 to 6	0 to 6	0 to 6
HAS-BLED score categories, n(%)	n (missing)	3032 (2037)	3540 (1961)	7275 (4384)	8587 (2881)	8814 (2456)	8760 (2612)	36976 (14294)	28216 (11682)
	0	392 (12.9)	377 (10.6)	913 (12.5)	1204 (14.0)	1457 (16.5)	1435 (16.4)	5386 (14.6)	3951 (14.0)
	1	1215 (40.1)	1420 (40.1)	2993 (41.1)	3585 (41.7)	3960 (44.9)	3932 (44.9)	15890 (43.0)	11958 (42.4)
	2	1021 (33.7)	1278 (36.1)	2372 (32.6)	2833 (33.0)	2522 (28.6)	2524 (28.8)	11529 (31.2)	9005 (31.9)
	3	317 (10.5)	386 (10.9)	858 (11.8)	810 (9.4)	737 (8.4)	745 (8.5)	3536 (9.6)	2791 (9.9)
	4	74 (2.4)	70 (2.0)	124 (1.7)	144 (1.7)	125 (1.4)	113 (1.3)	576 (1.6)	463 (1.6)
	5	12 (0.4)	9 (0.3)	14 (0.2)	11 (0.1)	12 (0.1)	10 (0.1)	56 (0.2)	46 (0.2)
	6-9	1 (0.0)	-	1 (0.0)	-	1 (0.0)	1 (0.0)	3 (0.0)	2 (0.0)

**Table 10: Treatment at baseline by CHA2DS2-VASc score**  
**Full Analysis Dataset : GLOBAL**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 1 retrospective	0	26	30.6	10	11.8	-	-	-	-	-	-	-	-	32	37.6	17	20	2
	1	277	45.9	59	9.8	6	1	1	0.2	-	-	-	-	173	28.6	88	14.6	18
	2	473	48.8	102	10.5	5	0.5	7	0.7	8	0.8	2	0.2	270	27.8	103	10.6	22
	3	563	50.3	131	11.7	6	0.5	8	0.7	3	0.3	3	0.3	310	27.7	96	8.6	26
	4	543	54.5	139	13.9	3	0.3	4	0.4	1	0.1	-	-	238	23.9	69	6.9	22
	5	303	50.2	93	15.4	4	0.7	8	1.3	2	0.3	-	-	157	26	36	6	10
6-9	186	45.4	80	19.5	4	1	7	1.7	3	0.7	3	0.7	105	25.6	22	5.4	21	
Cohort 1 prospective	0	39	27.5	7	4.9	1	0.7	2	1.4	-	-	-	-	54	38	39	27.5	-
	1	228	35.2	61	9.4	11	1.7	6	0.9	6	0.9	3	0.5	230	35.5	102	15.8	25
	2	392	38.9	114	11.3	10	1	9	0.9	9	0.9	4	0.4	335	33.3	134	13.3	43
	3	496	40.5	167	13.6	15	1.2	10	0.8	9	0.7	7	0.6	348	28.4	173	14.1	39
	4	507	45	159	14.1	15	1.3	17	1.5	11	1	10	0.9	299	26.6	108	9.6	43
	5	281	44.2	96	15.1	12	1.9	17	2.7	6	0.9	6	0.9	165	25.9	53	8.3	21
6-9	148	33.9	88	20.2	7	1.6	8	1.8	6	1.4	4	0.9	144	33	31	7.1	17	
Cohort 2	0	65	25.9	16	6.4	11	4.4	3	1.2	18	7.2	2	0.8	63	25.1	73	29.1	4
	1	418	31.7	84	6.4	59	4.5	17	1.3	88	6.7	14	1.1	408	30.9	231	17.5	9
	2	819	37	215	9.7	118	5.3	24	1.1	135	6.1	23	1	616	27.8	262	11.8	17
	3	1060	38.4	333	12.1	139	5	55	2	147	5.3	44	1.6	694	25.1	288	10.4	23
	4	978	39.4	343	13.8	132	5.3	62	2.5	131	5.3	41	1.7	581	23.4	213	8.6	22
	5	492	37.3	213	16.1	58	4.4	27	2	70	5.3	30	2.3	326	24.7	104	7.9	16
6-9	303	32	180	19	44	4.6	27	2.9	41	4.3	21	2.2	263	27.8	68	7.2	9	
Cohort 3	0	48	16.8	11	3.8	44	15.4	6	2.1	23	8	-	-	62	21.7	92	32.2	4
	1	323	24.1	72	5.4	181	13.5	24	1.8	111	8.3	10	0.7	332	24.7	290	21.6	9
	2	743	33.1	160	7.1	328	14.6	54	2.4	193	8.6	27	1.2	429	19.1	310	13.8	16
	3	914	34.1	231	8.6	402	15	81	3	196	7.3	37	1.4	509	19	309	11.5	27
4	828	33.6	254	10.3	394	16	93	3.8	171	6.9	39	1.6	442	17.9	246	10	26	

**Table 10: Treatment at baseline by CHA2DS2-VASc score**  
**Full Analysis Dataset : GLOBAL**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
	5	399	32.2	149	12	172	13.9	51	4.1	67	5.4	20	1.6	278	22.4	105	8.5	21
	6-9	251	31.3	124	15.5	108	13.5	45	5.6	39	4.9	12	1.5	170	21.2	52	6.5	12
Cohort 4	0	70	19.8	13	3.7	52	14.7	11	3.1	37	10.5	-	-	60	16.9	111	31.4	6
	1	296	21.9	45	3.3	320	23.7	25	1.9	120	8.9	11	0.8	255	18.9	277	20.5	8
	2	622	27.8	124	5.5	540	24.1	80	3.6	172	7.7	23	1	394	17.6	284	12.7	20
	3	729	27.9	204	7.8	755	28.9	120	4.6	138	5.3	27	1	382	14.6	259	9.9	38
	4	670	29.2	185	8.1	585	25.5	137	6	127	5.5	30	1.3	343	15	217	9.5	20
	5	299	25.1	129	10.8	286	24	79	6.6	73	6.1	19	1.6	219	18.4	89	7.5	13
	6-9	175	21.8	121	15	180	22.4	70	8.7	39	4.9	18	2.2	143	17.8	58	7.2	10
Cohort 5	0	40	11.3	14	3.9	84	23.7	6	1.7	27	7.6	1	0.3	61	17.2	122	34.4	2
	1	245	17.8	55	4	362	26.2	56	4.1	100	7.2	5	0.4	278	20.1	279	20.2	6
	2	475	22.1	136	6.3	649	30.1	96	4.5	177	8.2	30	1.4	334	15.5	256	11.9	14
	3	614	23.6	182	7	837	32.1	153	5.9	171	6.6	27	1	384	14.7	237	9.1	20
	4	584	24	190	7.8	736	30.3	142	5.8	160	6.6	31	1.3	355	14.6	232	9.5	28
	5	273	22.4	108	8.9	348	28.5	87	7.1	72	5.9	16	1.3	222	18.2	94	7.7	15
	6-9	124	15.9	99	12.7	210	27	104	13.4	43	5.5	10	1.3	136	17.5	53	6.8	10
Total Prospective patients Cohorts 1 to 5	0	262	18.9	61	4.4	192	13.8	28	2	105	7.6	3	0.2	300	21.6	437	31.5	16
	1	1510	25	317	5.3	933	15.5	128	2.1	425	7	43	0.7	1503	24.9	1179	19.5	57
	2	3051	31	749	7.6	1645	16.7	263	2.7	686	7	107	1.1	2108	21.4	1246	12.6	110
	3	3813	32.1	1117	9.4	2148	18.1	419	3.5	661	5.6	142	1.2	2317	19.5	1266	10.7	147
	4	3567	33	1131	10.5	1862	17.2	451	4.2	600	5.6	151	1.4	2020	18.7	1016	9.4	139
	5	1744	31.1	695	12.4	876	15.6	261	4.7	288	5.1	91	1.6	1210	21.6	445	7.9	86
	6-9	1001	26.6	612	16.2	549	14.6	254	6.7	168	4.5	65	1.7	856	22.7	262	7	58

**Table 10: Treatment at baseline by CHA2DS2-VASc score**  
**Full Analysis Dataset : GLOBAL**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Total	0	222	21.5	47	4.5	108	10.5	22	2.1	78	7.6	2	0.2	239	23.1	315	30.5	14	
Prospective patients																			
Cohorts 1 to 4																			
	1	1265	27.2	262	5.6	571	12.3	72	1.5	325	7	38	0.8	1225	26.3	900	19.3	51	
	2	2576	33.4	613	8	996	12.9	167	2.2	509	6.6	77	1	1774	23	990	12.9	96	
	3	3199	34.5	935	10.1	1311	14.1	266	2.9	490	5.3	115	1.2	1933	20.8	1029	11.1	127	
	4	2983	35.6	941	11.2	1126	13.5	309	3.7	440	5.3	120	1.4	1665	19.9	784	9.4	111	
	5	1471	33.5	587	13.4	528	12	174	4	216	4.9	75	1.7	988	22.5	351	8	71	
	6-9	877	29.4	513	17.2	339	11.3	150	5	125	4.2	55	1.8	720	24.1	209	7	48	



**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : GLOBAL**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 1 retrospective	0	306	80.3	-	-	4	1	-	-	1	0.3	-	-	-	-	70	18.4	11
	1	808	68	79	6.6	9	0.8	2	0.2	7	0.6	1	0.1	190	16	92	7.7	27
	2	345	34.6	186	18.7	5	0.5	6	0.6	-	-	2	0.2	402	40.3	51	5.1	24
	3	59	19.5	82	27.1	-	-	8	2.6	-	-	3	1	139	45.9	12	4	14
	4-9	13	15.5	25	29.8	-	-	1	1.2	-	-	-	-	44	52.4	1	1.2	3
Cohort 1 prospective	0	252	70.4	-	-	4	1.1	-	-	8	2.2	-	-	-	-	94	26.3	19
	1	749	54.8	102	7.5	18	1.3	10	0.7	15	1.1	7	0.5	310	22.7	157	11.5	52
	2	323	26.3	241	19.6	23	1.9	24	2	8	0.7	11	0.9	547	44.5	53	4.3	48
	3	54	14.6	93	25.2	4	1.1	15	4.1	4	1.1	6	1.6	170	46.1	23	6.2	17
	4-9	8	10.7	23	30.7	-	-	4	5.3	-	-	2	2.7	36	48	2	2.7	4
Cohort 2	0	513	56.8	-	-	81	9	-	-	87	9.6	-	-	-	-	222	24.6	10
	1	1482	50	168	5.7	212	7.2	22	0.7	229	7.7	22	0.7	511	17.2	319	10.8	28
	2	633	26.9	433	18.4	85	3.6	58	2.5	86	3.7	57	2.4	866	36.8	137	5.8	17
	3	145	17	216	25.3	25	2.9	29	3.4	19	2.2	27	3.2	355	41.6	37	4.3	5
	4-9	14	10.2	44	32.1	2	1.5	5	3.6	1	0.7	2	1.5	66	48.2	3	2.2	2
Cohort 3	0	478	40.2	-	-	216	18.2	-	-	148	12.4	-	-	-	-	347	29.2	15
	1	1377	38.8	174	4.9	650	18.3	40	1.1	332	9.4	24	0.7	497	14	455	12.8	36
	2	625	22.3	432	15.4	326	11.6	166	5.9	139	5	67	2.4	835	29.8	211	7.5	32
	3	167	20.9	138	17.3	69	8.6	47	5.9	21	2.6	22	2.8	272	34	64	8	10
	4-9	15	9.7	37	24	12	7.8	15	9.7	4	2.6	1	0.6	61	39.6	9	5.8	1
Cohort 4	0	507	35.4	-	-	392	27.4	-	-	171	11.9	-	-	-	-	361	25.2	26
	1	1244	31.8	163	4.2	1222	31.3	73	1.9	276	7.1	30	0.8	447	11.4	455	11.6	50
	2	455	18.2	316	12.6	449	17.9	244	9.7	103	4.1	48	1.9	702	28	186	7.4	19
	3	108	14.8	139	19	96	13.1	82	11.2	20	2.7	23	3.1	222	30.3	42	5.7	5
	4-9	16	11.8	41	30.1	12	8.8	13	9.6	1	0.7	3	2.2	42	30.9	8	5.9	2

**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : GLOBAL**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n		
Cohort 5	0	388	27.3	-	-	508	35.7	-	-	184	12.9	-	-	-	-	342	24.1	13
	1	992	25.5	171	4.4	1406	36.2	106	2.7	314	8.1	31	0.8	478	12.3	387	10	47
	2	375	15	312	12.5	535	21.4	275	11	102	4.1	55	2.2	675	27	171	6.8	24
	3	72	9.7	122	16.5	106	14.3	117	15.8	33	4.5	16	2.2	221	29.9	52	7	6
	4-9	12	9.7	26	21	11	8.9	16	12.9	1	0.8	2	1.6	50	40.3	6	4.8	-
Total Prospective patients Cohorts 1 to 5	0	2138	40.3	-	-	1201	22.6	-	-	598	11.3	-	-	-	-	1366	25.8	83
Total Prospective patients Cohorts 1 to 4	1	5844	37.3	778	5	3508	22.4	251	1.6	1166	7.4	114	0.7	2243	14.3	1773	11.3	213
	2	2411	21.2	1734	15.2	1418	12.5	767	6.7	438	3.8	238	2.1	3625	31.8	758	6.7	140
	3	546	15.6	708	20.3	300	8.6	290	8.3	97	2.8	94	2.7	1240	35.5	218	6.2	43
	4-9	65	10.4	171	27.3	37	5.9	53	8.5	7	1.1	10	1.6	255	40.7	28	4.5	9
	0	1750	45.1	-	-	693	17.9	-	-	414	10.7	-	-	-	-	1024	26.4	70
Total Prospective patients Cohorts 1 to 4	1	4852	41.1	607	5.1	2102	17.8	145	1.2	852	7.2	83	0.7	1765	15	1386	11.8	166
	2	2036	22.9	1422	16	883	9.9	492	5.5	336	3.8	183	2.1	2950	33.2	587	6.6	116
	3	474	17.2	586	21.3	194	7	173	6.3	64	2.3	78	2.8	1019	37	166	6	37
	4-9	53	10.6	145	28.9	26	5.2	37	7.4	6	1.2	8	1.6	205	40.8	22	4.4	9
	0	1750	45.1	-	-	693	17.9	-	-	414	10.7	-	-	-	-	1024	26.4	70

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : GLOBAL**

Variable	Statistics	Cohort 1 Prospective patients (N=2828) (n %)	Cohort 2 (N=5612) (n %)	Cohort 3 (N=4634) (n %)	Cohort 4 (N=3778) (n %)	Total Prospective patients Cohorts 1 to 4 (N=16852)
TTR value, n(%)	n (missing)	1706 (1122)	3438 (2174)	2793 (1841)	1997 (1781)	9934 (6918)
	<65	996 (58.4)	1967 (57.2)	1666 (59.6)	1222 (61.2)	5851 (58.9)
	>=65	710 (41.6)	1471 (42.8)	1127 (40.4)	775 (38.8)	4083 (41.1)
TTR	n (missing)	1706 (1122)	3438 (2174)	2793 (1841)	1997 (1781)	9934 (6918)
	Mean (SD)	55.6 (27.5)	56.3 (26.6)	54.2 (27.1)	53.3 (28.4)	55.0 (27.3)
	Median (IQR)	59.2 (37.3 to 76.4)	60.3 (39.1 to 76.4)	58.0 (35.1 to 75.0)	57.3 (32.3 to 75.6)	58.8 (36.7 to 75.8)
	Min to Max	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0
INR value, n(%)	n	22369	48885	39583	26296	137133
	2-3	11541 (51.6)	25511 (52.2)	20167 (50.9)	13324 (50.7)	70543 (51.4)
	<2	7061 (31.6)	15093 (30.9)	12900 (32.6)	8911 (33.9)	43965 (32.1)
	>3	3767 (16.8)	8281 (16.9)	6516 (16.5)	4061 (15.4)	22625 (16.5)
INR	n	22369	48885	39583	26296	137133
	Mean (SD)	2.4 (0.9)	2.4 (0.9)	2.4 (0.9)	2.4 (0.9)	2.4 (0.9)
	Median (IQR)	2.3 (1.9 to 2.8)	2.3 (1.9 to 2.8)	2.3 (1.8 to 2.8)	2.2 (1.8 to 2.7)	2.3 (1.8 to 2.8)
	Min to Max	0.8 to 15.5	0.8 to 20.0	0.8 to 20.0	0.8 to 17.0	0.8 to 20.0

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : GLOBAL**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		39898	1603	4.25	(4.05 to 4.46)
	<b>Cardiovascular death</b>	39898	643	1.71	(1.58 to 1.84)
	<b>Non-Cardiovascular death</b>	39898	581	1.54	(1.42 to 1.67)
	<b>Undetermined cause</b>	39898	379	1.01	(0.91 to 1.11)
Stroke/SE		39898	537	1.43	(1.32 to 1.56)
Major bleed		39898	328	0.87	(0.78 to 0.97)
Acute coronary syndrome		39898	306	0.81	(0.73 to 0.91)
Congestive Heart Failure		39898	899	2.42	(2.26 to 2.58)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : GLOBAL**

		GLOBAL		
Outcome	Cause	N	Events	%
<b>Cardiovascular causes</b>	missing	643	2	0.31
	Myocardial infarction	643	69	10.73
	Ischaemic stroke	643	69	10.73
	Congestive heart failure	643	211	32.82
	Sudden or unwitnessed death	643	109	16.95
	Other	643	183	28.46
<b>Non-cardiovascular causes</b>	missing	581	3	0.52
	Accidental / trauma	581	14	2.41
	Respiratory failure	581	115	19.79
	Infection/sepsis	581	111	19.11
	Malignancy	581	167	28.74
	Other	581	171	29.43

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset :GLOBAL**

OUTCOME	GLOBAL		
	N	Events	%
Stroke(not including systemic embolism)	39898	483	1.21
Primary Ischemic Stroke	39898	327	0.82
<i>of which secondary hemorrhagic ischemic</i>	39898	18	0.05
<b>Primary intracerebral hemorrhage*</b>	39898	62	0.16
<i>Intracerebral</i>	39898	38	0.10
<i>Subarachnoid</i>	39898	10	0.03
<i>Intraventricular</i>	39898	8	0.02
<i>Subdural Hematoma</i>	39898	2	0.01
<i>Epidural Hematoma</i>	39898	1	0.00
Undetermined	39898	94	0.24

\*Note :Multiple choice question type that allows the respondent to choose one or multiple options from the list of possible answers.

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : GLOBAL**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	1047	980.88	13	1.33	(0.77 to 2.28)
1	4709	4489.57	58	1.29	(1.00 to 1.67)
2	7798	7435.96	173	2.33	(2.00 to 2.70)
3	9405	8938.06	323	3.61	(3.24 to 4.03)
4+	15976	14965.46	1000	6.68	(6.28 to 7.11)
Unknown	963	903.32	36	3.99	(2.88 to 5.53)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : GLOBAL**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	1047	979.56	4	0.41	(0.15 to 1.09)
1	4709	4479.32	22	0.49	(0.32 to 0.75)
2	7798	7398.29	80	1.08	(0.87 to 1.35)
3	9405	8890.39	108	1.22	(1.01 to 1.47)
4+	15976	14838.64	317	2.14	(1.91 to 2.39)
Unknown	963	900.46	6	0.67	(0.30 to 1.48)



**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : GLOBAL**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	1047	979.21	4	0.41	(0.15 to 1.09)
1	4709	4484.83	14	0.31	(0.19 to 0.53)
2	7798	7415.04	44	0.59	(0.44 to 0.80)
3	9405	8899.67	82	0.92	(0.74 to 1.14)
4+	15976	14889.39	176	1.18	(1.02 to 1.37)
Unknown	963	899.41	8	0.89	(0.45 to 1.78)